Forecast

There is no analyst data available for this company.

News Go to news feed

Medicure presents phase‑3 data on MC‑1 for PNPO deficiency at epilepsy congress

Medicure presented the design, rationale and initial baseline data of the phase‑3 MEND‑PNPO study of the oral P5P formulation MC‑1 for treatment of the rare PNPO deficiency at the 16th European Epilepsy Congress. The open‑label, multicenter 52‑week study began in January 2023 and targets about 10 genetically confirmed patients aged two years and older; so far nine patients have been enrolled and three have completed the one‑year follow‑up. Starting doses ranged from 14 to 58 mg/kg/day, measured steady‑state P5P levels were 59.8–165 ng/ml, and MC‑1 is not yet approved by the FDA. Medicure also plans to present the study at upcoming professional congresses in Montreal and Denver. » More on de.investing.com
Medicure increases Q2 revenue thanks to ZYPITAMAG and pharmacies, reports larger net loss

Medicure reported Q2 2026 net revenue of CAD 7.4 million (+10.4% vs. year‑ago), driven by ZYPITAMAG and its pharmacy network, which accounted for about 79.9% of revenue. Adjusted EBITDA improved to CAD 172,000, but the reported net loss widened to CAD 1.4 million, mainly due to a CMS-related rebate liability (CAD 864,000) and higher R&D spending for the Phase III MC-1 program. AGGRASTAT sales fell 61.1% on intensified generic competition, and cash declined to CAD 1.8 million. Management emphasizes a focus on further growth of ZYPITAMAG, integration of the pharmacies and progress on MC-1, but did not provide formal guidance. » More on de.investing.com
Medicure records 43.6% revenue growth in Q1 2026

Medicure reports a 43.6% revenue increase in Q1 2026 to CAD 7.9 million and narrowed its net loss to CAD 406,000, or -0.04 CAD per share. Growth was driven mainly by ZYPITAMAG (revenue through insurance channels +150.3%) and pharmacy acquisitions, while AGGRASTAT declined 42.4% due to generic competition. Cash fell to CAD 1.5 million; the company forecasts revenues of CAD 25.06 million for 2026 and CAD 28.2 million for 2027 and is focusing on expanding its pharmacy business. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Medicure has already paid €91.14 in dividends. The last payout was in November 2022.

Financials

In the last quarter, Medicure had revenue of €4.58m and net profit of -€880.66k

(EUR)	June 2026	YoY
Revenue	4.58m	10.14%
Gross profit	1.97m	7.92%
Net profit	-880.66k	79.69%
EBITDA	-355.84k	901.17%

Fundamentals

Metric	Value
Market capitalization	€16.46m
Number of shares	10.44m
52-week high/low	€1.64 - €0.58
Dividends	No
Beta	1.04
P/E ratio	-3.53
PEG ratio	0.04
P/B ratio	2.25
P/S ratio	0.81

Company profile

Medicure Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Erforschung, Entwicklung und Vermarktung von Humantherapien für den kardiovaskulären Markt in Kanada und den Vereinigten Staaten beschäftigt. Das Unternehmen vermarktet und vertreibt AGGRASTAT-Injektion, einen Glykoprotein-GP IIb/IIIa-Rezeptor-Antagonisten für die Behandlung des akuten Koronarsyndroms, einschließlich instabiler Angina pectoris und Nicht-Q-Wellen-Myokardinfarkt. Außerdem bietet es ZYPITAMAG zur Behandlung von Patienten mit primärer Hyperlipidämie oder gemischter Dyslipidämie an. Darüber hinaus bietet das Unternehmen ReDS an, ein nicht-invasives medizinisches Gerät, das die Messung von Lungenflüssigkeit für das Management von kongestiver Herzinsuffizienz ermöglicht. Darüber hinaus bietet das Unternehmen Natriumnitroprussid-Injektionen zur Senkung des Blutdrucks bei erwachsenen und pädiatrischen Patienten in hypertensiven Krisen sowie zur Erzeugung einer kontrollierten Hypotonie zur Verringerung von Blutungen bei Operationen und zur Behandlung von akuter Herzinsuffizienz an. Das Unternehmen bietet seine Produkte sowohl über den Apothekenhandel als auch online an. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in Winnipeg, Kanada.